Erector Spinae vs. PENG Block for Total Hip Arthroplasty
CompletedPhase 4NCT06083428
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Effect of PENG block and ESPB on pain management, and NLR and PLR following knee arthroplasty
Study details
- Official title
- Erector Spinae Plane Block (ESPB) vs. PENG Block for Pain Management and Stress Response in Patients Undergoing Total Hip Arthroplasty. A Prospective, Randomized Trial.
- Conditions
- Hip Arthropathy
- Hip Osteoarthritis
- Hip Pain Chronic
- Interventions
- Drug: Ropivacaine 0.2% Injectable Solution Erector Spinae Plane Block
- Drug: Ropivacaine 0.2% Injectable Solution - PENG block
- Drug: Control Test
- Sponsor
- Poznan University of Medical Sciences
- Start date
- 2023-10-17
- Primary completion
- 2024-06-11
- Sex
- All
- Age range
- from 20 Years to 90 Years
- Results posted
- No results posted in this snapshot
- Countries
- Poland
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients with ASA classification I-III, Aged 20-90 years, Who will be scheduled for hip arthroplasty under spinal anesthesia. Exclusion Criteria: * Patients who have a history of bleeding diathesis, Take anticoagulant therapy, have a History of chronic pain before surgery, have Multiple trauma, cannot assess their pain (dementia), have been operated on under general anesthesia, have an infection in the area and do not accept the procedure
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06083428